# The Randomized OPTIMAL-ACT Trial

> **NCT03772613** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 180 (actual)

## Conditions studied

- Coronary Artery Disease
- Ischemic Heart Disease
- Anticoagulant-induced Bleeding
- Coronary Syndrome

## Interventions

- **DRUG:** Unfractionated heparin

## Key facts

- **NCT ID:** NCT03772613
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-08
- **Primary completion:** 2021-10-25
- **Final completion:** 2021-10-25
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03772613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03772613, "The Randomized OPTIMAL-ACT Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03772613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*